Filtros de búsqueda

Lista de obras de

A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer

artículo científico publicado en 2011

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling

artículo científico publicado en 2016

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

artículo científico publicado en 2009

A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation

artículo científico publicado en 2019

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

artículo científico publicado en 2016

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

artículo científico publicado en 2007

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

artículo científico publicado en 2005

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer

artículo científico publicado en 2015

A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors

artículo científico publicado en 2013

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

artículo científico publicado en 2014

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility

artículo científico publicado en 2017

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

artículo científico publicado en 2015

Abiraterone in metastatic prostate cancer without previous chemotherapy

artículo científico publicado en 2013

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

artículo científico publicado en 2006

Acceptability of Fitbit for physical activity tracking within clinical care among men with prostate cancer

artículo científico publicado en 2016

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

artículo científico publicado en 2020

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article published on 06 February 2019

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer

artículo científico publicado en 2007

Analysis and sorting of prostate cancer cell types by flow cytometry

artículo científico publicado en 1999

Androgen Deprivation for Prostate Cancer: When and How, the Good and the Bad ⬇️

artículo científico publicado el 1 de enero de 2013

Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens

artículo científico publicado en 2018

Androgen deprivation therapy: monitoring and managing the complications

artículo científico publicado en 2006

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

artículo científico publicado en 2017

Androgen-deprivation therapy for prostate cancer.

artículo científico publicado en 2003

Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

artículo científico publicado en 2008

Annual zoledronic acid: is less more?

artículo científico publicado en 2007

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

artículo científico publicado en 2010

Assessing the nutritional needs of men with prostate cancer

artículo científico publicado en 2019

Back to Basics: Addressing Bone Health in Men with Prostate Cancer on Androgen Deprivation Therapy

scientific article published on 01 August 2019

Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results

artículo científico publicado el 1 de enero de 2003

Bone loss and the evolving role of bisphosphonate therapy in prostate cancer

artículo científico publicado en 2003

Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis

artículo científico publicado en 1987

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

artículo científico publicado en 2004

C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy

artículo científico publicado en 2011

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity

artículo científico publicado en 2010

COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.

artículo científico publicado en 2009

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

artículo científico publicado en 2014

Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer

artículo científico publicado en 2020

Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment ⬇️

artículo científico publicado el 11 de agosto de 2013

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

artículo científico publicado en 2015

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer

artículo científico publicado en 2018

Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study

artículo científico publicado en 2010

Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases ⬇️

artículo científico publicado el 17 de enero de 2013

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer

artículo científico publicado en 2016

Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes

artículo científico publicado en 2014

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.

artículo científico publicado en 2017

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

artículo científico publicado en 2014

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial

artículo científico publicado en 2014

Clinic Utilization and Characteristics of Patients Accessing a Prostate Cancer Supportive Care Program's Sexual Rehabilitation Clinic

artículo científico publicado en 2020

Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer

artículo científico publicado en 2020

Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer

artículo científico publicado en 2009

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel

artículo científico publicado en 2020

Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer

artículo científico publicado en 2009

Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients

artículo científico publicado en 1988

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2020

Conventional treatments of localized prostate cancer.

artículo científico publicado en 2008

Correction to: Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors

scientific article published on 01 November 2019

Current recommendations for prostate cancer genetic testing: NCCN prostate guideline

scientific article published on 01 October 2019

Current status of treatment for patients with metastatic prostate cancer

artículo científico publicado en 2005

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

artículo científico publicado en 2017

Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer

scientific article published on 01 June 2007

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

artículo científico publicado en 2009

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

artículo científico publicado en 2008

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer

artículo científico

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

scientific article published on 01 November 2018

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

artículo científico publicado en 2009

Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases

artículo científico

Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database

artículo científico publicado en 2016

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

artículo científico publicado en 2013

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.

artículo científico publicado en 2016

Does chemotherapy have a role before hormone-resistant disease develops?

scientific article published on May 2009

Does nonmetastatic castration-resistant prostate cancer still exist?

artículo científico publicado en 2018

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

artículo científico publicado en 2007

Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect

artículo científico publicado en 1990

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation

artículo científico publicado en 2010

Editorial Comment

scientific article published on 24 July 2018

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial

artículo científico publicado en 2017

Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial

artículo científico publicado en 2014

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomi

artículo científico publicado en 2015

Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series ⬇️

artículo científico publicado el 1 de febrero de 2013

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort

artículo científico publicado en 2014

Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy

artículo científico

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.

artículo científico publicado en 2015

Elevation of cytokine levels in cachectic patients with prostate carcinoma

artículo científico publicado en 2003

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

artículo científico publicado en 2004

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

artículo científico publicado en 2016

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

artículo científico publicado en 2016

Enzalutamide in metastatic prostate cancer before chemotherapy

artículo científico publicado en 2014

Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer ⬇️

artículo científico publicado el 1 de abril de 2013

Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

scientific article published on 01 June 2019

Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases

artículo científico publicado en 2015

Erectile function outcome reporting after clinically localized prostate cancer treatment

artículo científico publicado en 2007

Estrogenic side effects of androgen deprivation therapy.

artículo científico publicado en 2007

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details

artículo científico publicado en 2015

Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.

artículo científico publicado en 2017

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

artículo científico publicado en 2018

Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV

artículo científico publicado en 2020

Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia

artículo científico publicado en 2003

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

artículo científico publicado en 2020

Four-year overview of enrollment and participation in research studies conducted at the Prostate Cancer Supportive Care (PCSC) Program. ⬇️

artículo científico publicado en 2019

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

artículo científico publicado en 2013

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

artículo científico publicado en 2019

Germline and Somatic Mutations in Prostate Cancer for the Clinician

scientific article published on 01 May 2019

Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation

artículo científico publicado en 2000

Guideline for the management of clinically localized prostate cancer: 2007 update.

artículo científico publicado en 2007

Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

artículo científico publicado en 2010

Histopathological assessment of prostate cancer bone osteoblastic metastases

artículo científico publicado en 2008

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

artículo científico publicado en 2015

Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data

scientific article published on 22 October 2020

Impact of androgen deprivation therapy on mood, cognition, and risk for AD

artículo científico publicado en 2019

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

artículo científico publicado en 2012

In Reply

article published in 2008

Influence of infusion duration on the efficacy and toxicity of intravenous cyclosporine in bone marrow transplant patients

scientific article published on 01 June 1988

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

artículo científico publicado en 2009

Integration of immunotherapy into the management of advanced prostate cancer ⬇️

artículo científico publicado el 1 de septiembre de 2012

Intermittent Androgen Deprivation Therapy-An Important Treatment Option for Prostate Cancer

artículo científico publicado en 2016

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy

artículo científico publicado en 2015

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel

artículo científico publicado en 2014

Intermittent androgen deprivation: clinical experience and practical applications

artículo científico publicado en 2006

Intermittent androgen suppression for rising PSA level after radiotherapy

artículo científico publicado en 2012

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

scientific article published on 01 November 1996

Intermittent versus continuous androgen deprivation in prostate cancer

artículo científico publicado en 2013

Intermittent versus continuous androgen deprivation therapy

artículo científico publicado en 2014

Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer

scientific article published on 30 June 2020

Introduction to the seminar series: Optimal management during ADT to mitigate complications

scientific article published on 07 December 2018

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

artículo científico publicado en 2013

Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.

artículo científico publicado en 2008

Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer ⬇️

artículo científico publicado el 9 de abril de 2012

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer

artículo científico publicado en 2015

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

artículo científico publicado en 2017

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

artículo científico publicado en 2008

Management of Bone Loss in Men With Prostate Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2003

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

artículo científico publicado en 2020

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

artículo científico publicado en 2017

Mapping the course after CHAARTED

artículo científico publicado en 2015

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

artículo científico publicado en 2016

Metastases of prostate cancer express estrogen receptor-beta

artículo científico publicado en 2004

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment

artículo científico publicado en 2018

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy

scientific article published on 10 September 2019

Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity

artículo científico publicado en 2004

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer

artículo científico publicado en 2016

Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.

artículo científico publicado en 2007

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

artículo científico publicado en 2019

Multimarker circulating DNA assay for assessing blood of prostate cancer patients

scientific article published on 08 January 2009

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

artículo científico publicado en 2015

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

artículo científico publicado en 2005

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer

artículo científico publicado en 2001

Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer

artículo científico publicado en 2006

New and emerging agents for the treatment of castration-resistant prostate cancer ⬇️

artículo científico publicado el 1 de noviembre de 2011

New developments in the treatment of castration-resistant prostate cancer

artículo científico publicado en 2014

New treatment options for patients with metastatic castration-resistant prostate cancer ⬇️

artículo científico publicado el 23 de septiembre de 2011

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

artículo científico publicado en 2020

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

artículo científico publicado en 2016

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer

artículo científico

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

artículo científico publicado en 2004

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel

artículo científico publicado en 2018

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine ⬇️

artículo científico publicado el 6 de abril de 2011

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors

artículo científico publicado en 2019

Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic

artículo científico publicado en 2020

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling

artículo científico publicado en 2018

Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis

artículo científico publicado en 2013

Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer

artículo científico publicado en 2014

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

artículo científico publicado en 2008

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

artículo científico publicado en 2010

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

artículo científico

Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone ⬇️

artículo científico publicado el 11 de julio de 2012

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2019

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer

artículo científico publicado en 2004

Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections

artículo científico publicado en 1991

Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation

artículo científico publicado en 1991

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

artículo científico publicado en 2007

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

artículo científico publicado en 2008

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer ⬇️

artículo científico publicado el 8 de abril de 2013

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer ⬇️

artículo científico publicado el 5 de febrero de 2013

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone

artículo científico publicado en 2003

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

artículo científico publicado en 2006

Positive surgical margins: the argument for androgen deprivation and chemotherapy

scientific article published on January 2009

Potential use of custirsen to treat prostate cancer ⬇️

artículo científico publicado el 25 de junio de 2013

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC

artículo científico publicado en 2020

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer

artículo científico publicado en 2017

Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients

artículo científico publicado en 1990

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial

artículo científico publicado en 2018

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation

artículo científico publicado en 2015

Prostate Cancer National Summit's Call to Action

artículo científico publicado en 2019

Prostate Cancer, Version 1.2016.

artículo científico publicado en 2016

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2019

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines ⬇️

artículo científico publicado el 1 de septiembre de 2012

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis

artículo científico publicado en 2014

Prostate cancer, version 1.2014.

artículo científico publicado en 2013

Prostate cancer, version 2.2014

artículo científico publicado en 2014

Prostate cancer-associated gene expression alterations determined from needle biopsies

artículo científico publicado en 2009

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

artículo científico publicado en 2009

Quality indicators for global benchmarking of localised prostate cancer management

artículo científico publicado en 2018

Quantitative and stoichiometric analysis of the microRNA content of exosomes

artículo científico publicado en 2014

Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression

artículo científico publicado en 2012

Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial

artículo científico publicado en 2018

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

artículo científico publicado en 2017

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results

artículo científico publicado en 2015

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

scientific article published on 11 May 2019

Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study

artículo científico publicado en 2017

Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

artículo científico publicado en 2012

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer

scientific article published on 04 September 2019

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

artículo científico publicado en 2009

Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer

artículo científico publicado en 2014

Reply form Authors re: Bertrand Tombal. Continuous Improvement Versus Innovation: The Case for Sipuleucel-T. Eur Urol 2012;61:648–9

article

Reply to M.A.N. Şendur et al and J. Michels

artículo científico publicado en 2016

Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data

scientific article published on 10 March 2020

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

artículo científico publicado en 2020

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer

artículo científico publicado en 2015

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer

artículo científico publicado en 2015

Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone

artículo científico publicado en 2008

Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer

artículo científico publicado en 2004

Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

artículo científico publicado en 2014

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial

scientific article published on 19 November 2018

Sexual Health After Cancer Therapy

artículo científico publicado en 2016

Sexuality and Intimacy After Definitive Treatment and Subsequent Androgen Deprivation Therapy for Prostate Cancer ⬇️

artículo científico publicado el 24 de septiembre de 2012

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

artículo científico publicado en 2003

Sipuleucel-T

scientific article published on 01 July 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

artículo científico publicado en 2010

Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma

artículo científico publicado en 2005

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

scientific article published on 29 February 2016

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

scientific article published on 28 February 2020

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial ⬇️

artículo científico publicado en 2021

Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go?

artículo científico publicado en 2014

The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy

scientific article published on 31 December 2020

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data

scientific article published on 03 October 2019

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

artículo científico publicado en 2016

The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer

artículo científico publicado en 2017

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel

artículo científico publicado en 2006

The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature

artículo científico

The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation

artículo científico publicado en 1990

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment

artículo científico publicado en 2003

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

artículo científico publicado en 2014

To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer

artículo científico publicado en 2014

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies

artículo científico publicado en 2015

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States

artículo científico publicado en 2020

Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

artículo científico publicado en 2008

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

artículo científico publicado en 2012

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

artículo científico publicado en 2016

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.

artículo científico publicado en 2016

Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases ⬇️

artículo científico publicado el 1 de julio de 2013

Two-year review of the electronic Patient Reported Outcome (ePRO) system in the Prostate Clinic at the Vancouver Prostate Centre (VPC). ⬇️

artículo científico publicado en 2019

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician

artículo científico publicado en 2004

Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer

artículo científico publicado en 2020

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

artículo científico publicado en 2014

Urological cancer: α-emitting radium-223-additional choices, more unknowns

scientific article published on 10 September 2013

Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation ⬇️

artículo científico publicado el 1 de octubre de 1997

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

artículo científico publicado en 2017

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

artículo científico publicado en 2007

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer

artículo científico publicado en 2003

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda